Submissions from 2025
Mergers and Acquisitions (M&As) in Pharmaceutical Markets: Associations with Market Concentration, Prices, Drug Quantity Sold, and Shortages, J. Daniel McGeeney M.S., Aylin Sertkaya Ph.D., Leah Ross M.A., Fred Ledley M.D., and Cody Hyman Ph.D.
Submissions from 2024
Tech Note 2024-1 A Novel Framework to Estimate Social and Private Value Created Through Commercialization of a Pharmaceutical Product, Paula Chaves de Silva and Fred D. Ledley
Comments Re: Draft Guidance Considering Exercise of March-In Rights - Docket No.: 230831-0207, Fred D. Ledley and Edward Zhou
Comments Re: Draft NIH Intramural Research Program Policy: Promoting Equity Through Access Planning, Fred Ledley M.D., Edward Zhou PharmD., and Paula Chaves da Silva Ph.D.
Medicare Drug Price Negotiation Program Draft Guidance, Fred Ledley M.D., Edward Zhou PharmD, and Paula Chaves da Silva Ph.D.
Submissions from 2023
Response to "Department of Commerce, National Institute of Standards and Technology, Agency Information Collection Activities", Fred D. Ledley
Comments Re: Workshop on Transforming Discoveries into Products: Maximizing NIH’s Levers to Catalyze Technology Transfer, Fred D. Ledley M.D.; Edward Zhou Pharm. D; and Paula Chaves da Silva, Ph. D.
Tech Note 2023-1 NIH Contribution to Phased Clinical Development of Drugs Approved from 2010-2019, Edward Zhou, Matthew Jackson, and Fred Ledley
Submissions from 2020
Characterizing the public sector contribution to drug discovery and development: the role of government as a first investor, Ekaterina Galkina Cleary, Matthew Jackson, Andrew Acevedo, and Fred D. Ledley
